Key result
Continuous infusion of JTV-519 significantly decreased the mean number of sustained atrial fibrillation episodes from 4.2 to 0 (P<0.01) in a canine sterile pericarditis model.
Why the study?
Does JTV-519 reduce the inducibility of atrial fibrillation/flutter in a canine sterile pericarditis model?
Population
9 dogs with a sterile pericarditis model, in which 38 episodes of sustained atrial fibrillation and 24…
Comparison
Continuous infusion of JTV-519 (0.03 mg/kg/min) vs Baseline (before infusion of JTV-519)
Design
Preclinical
Authors
Loading...
Should not change practice; leaves open whether JTV-519 prevents AF in humans.
Does JTV-519 reduce the inducibility of atrial fibrillation/flutter in a canine sterile pericarditis model?
Absolute Event Rate: 0% vs 4.2%
p-value: p=< 0.01
JTV-519 prevents atrial fibrillation in a canine sterile pericarditis model by prolonging the atrial effective refractory period, suggesting potential as a novel antiarrhythmic agent.
Kumagai et al. (2003) studied Atrial fibrillation/flutter (n=9). JTV-519 vs. Baseline (before infusion) was evaluated on Mean number of sustained atrial fibrillation episodes (p=< 0.01). Continuous infusion of JTV-519 significantly decreased the mean number of sustained atrial fibrillation episodes from 4.2 to 0 (P<0.01) in a canine sterile pericarditis model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: